We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

56 hedge funds and large institutions have $8.44M invested in Biotech Acquisition Company Warrant in 2021 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 4

44% more funds holding

Funds holding: 39 → 56 (+17)

30% more capital invested

Capital invested by funds: $6.51M → $8.44M (+$1.93M)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Holders
56
Holders Change
+17
Holders Change %
+43.59%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
5
Reduced
8
Closed
4
Calls
$5.78M
Puts
–
Net Calls
+$5.78M
Net Calls Change
+$4.42M

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$736K
2
HIM
HGC Investment Management
Ontario, Canada
+$382K
3
MF
Magnetar Financial
Illinois
+$153K
4
QGA
Q Global Advisors
Texas
+$87.3K
5
AC
Antara Capital
New York
+$76.3K

Top Sellers

Rank Fund Capital Flow
1
DCM
DG Capital Management
New York
-$148K
2
Nomura Holdings
Nomura Holdings
Japan
-$127K
3
Citadel Advisors
Citadel Advisors
Florida
-$122K
4
RA
Ramius Advisors
New York
-$119K
5
MI
MMCAP International
Cayman Islands
-$111K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
26
Rivernorth Capital Management
Florida
$73K – – –
AC
27
Antara Capital
New York
$72K +$76.3K +110,000 New
AGM
28
Alpine Global Management
New York
$67K +$71.8K +103,502 New
ACA
29
Arena Capital Advisors
California
$66K – – –
PSAMP
30
P. Schoenfeld Asset Management (PSAM)
New York
$66K – – –
CH
31
CVI Holdings
Delaware
$65K – – –
CCM
32
Context Capital Management
California
$64K +$67.4K +97,200 New
GCL
33
Glazer Capital LLC
New York
$52K +$54.9K +79,079 New
CAC
34
Cowen and Company
New York
$51K +$54K +77,771 New
ICMH
35
Integrity Capital Management (HK)
Hong Kong
$49K +$51.5K +74,272 New
JP Morgan Chase
36
JP Morgan Chase
New York
$47K – – –
WA
37
Whitebox Advisors
Minnesota
$41K +$43.4K +62,500 New
SCM
38
Shaolin Capital Management
Florida
$35K +$37.1K +53,444 New
Jane Street
39
Jane Street
New York
$34K +$1.34K +1,938 +4%
CP
40
Centerbridge Partners
New York
$33K – – –
Walleye Capital
41
Walleye Capital
New York
$33K +$34.2K +49,352 New
CCFM
42
Cohen & Co Financial Management
New York
$33K +$34.7K +50,000 New
CCA
43
Castle Creek Arbitrage
Colorado
$31K – – –
Walleye Trading
44
Walleye Trading
New York
$26K +$27.7K +40,000 New
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$25K +$26K +37,500 New
WAM
46
Wolverine Asset Management
Illinois
$22K -$11.9K -17,088 -33%
YCM
47
Yakira Capital Management
Connecticut
$18K +$18.7K +26,908 New
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$17K -$3.15K -4,544 -15%
PFM
49
Privium Fund Management
Netherlands
$17K +$19.4K +28,004 New
PCM
50
Prelude Capital Management
New York
$12K +$1.49K +2,150 +13%
1
2
3

BIOTW Hedge Fund Activity: Q4 2021 in Review

56 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q4 2021, worth a combined $8.44M — up 30% from $6.51M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new BIOTW positions and 4 closed out — a net gain of 17 holders — while 5 added to existing stakes and 8 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $736K. The largest seller was DG Capital Management, exiting entirely with an estimated $148K sold.

  • 56 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q4 2021, up from 39 in Q3 2021.
  • Funds reported $8.44M of Biotech Acquisition Company Warrant stock for Q4 2021, up 30% quarter-over-quarter.
  • 21 funds opened new Biotech Acquisition Company Warrant positions in Q4 2021 and 4 closed out, a net change of +17 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q4 2021 was Aristeia Capital, an estimated $736K added.
  • The largest Biotech Acquisition Company Warrant seller in Q4 2021 was DG Capital Management, an estimated $148K sold.

Based on aggregated 13F filings for Q4 2021.